Literature DB >> 10832594

Inhibition of HGF/SF-induced breast cancer cell motility and invasion by the HGF/SF variant, NK4.

S Hiscox1, C Parr, T Nakamura, K Matsumoto, R E Mansel, W G Jiang.   

Abstract

NK4 is a variant form of HGF/SF, comprising the N-terminal and subsequent four kringle domains of mature HGF/SF. HGF/SF is a multifunctional cytokine that enhances the metastatic behaviour of tumour cells in vitro by stimulation of the c-met receptor tyrosine kinase and has been implicated in the development of tumour metastasis in vivo. The aims of this study were to further investigate the potential antagonistic effects of the recently described variant form of HGF/SF, NK4, on HGF/SF activity in breast cancer cells. All cell lines used expressed both the HGF/SF receptor gene and protein as shown by RT-PCR and Western blotting. NK4 inhibited HGF/SF-induced tumour cell invasion through an artificial basement membrane. Tumour cell motility and scattering induced by HGF/SF were also dramatically reduced by the inclusion of NK4. Immunoprecipitation studies revealed that NK4 inhibited the phosphorylation of the c-met receptor in response to HGF/SF. Treatment of these cells with NK4 alone did not have any significant effects on their metastatic behaviour. From this data we conclude that NK4 demonstrates significant antagonistic properties towards HGF/SF, inhibiting HGF/SF-stimulated breast tumour cell invasion, motility and migration. NK4 may therefore be of potential benefit in the development of anti-metastasis therapies.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10832594     DOI: 10.1023/a:1006348317841

Source DB:  PubMed          Journal:  Breast Cancer Res Treat        ISSN: 0167-6806            Impact factor:   4.872


  7 in total

1.  Semaphorin SEMA3F has a repulsing activity on breast cancer cells and inhibits E-cadherin-mediated cell adhesion.

Authors:  Patrick Nasarre; Sophie Kusy; Bruno Constantin; Valérie Castellani; Harry A Drabkin; Dominique Bagnard; Joëlle Roche
Journal:  Neoplasia       Date:  2005-02       Impact factor: 5.715

Review 2.  Breast cancer stem cells, cytokine networks, and the tumor microenvironment.

Authors:  Hasan Korkaya; Suling Liu; Max S Wicha
Journal:  J Clin Invest       Date:  2011-10-03       Impact factor: 14.808

3.  Tamoxifen resistance in breast cancer cells is accompanied by an enhanced motile and invasive phenotype: inhibition by gefitinib ('Iressa', ZD1839).

Authors:  Stephen Hiscox; Liam Morgan; Denise Barrow; Carol Dutkowskil; Alan Wakeling; Robert I Nicholson
Journal:  Clin Exp Metastasis       Date:  2004       Impact factor: 5.150

Review 4.  Breast cancer stem cells: Multiple capacities in tumor metastasis.

Authors:  Shao-Qing Geng; Aris T Alexandrou; Jian Jian Li
Journal:  Cancer Lett       Date:  2014-04-12       Impact factor: 8.679

5.  Gene transduction of NK4, HGF antagonist, inhibits in vitro invasion and in vivo growth of human pancreatic cancer.

Authors:  Naoki Maehara; Eishi Nagai; Kazuhiro Mizumoto; Norihiro Sato; Kunio Matsumoto; Toshikazu Nakamura; Ko Narumi; Toshihiro Nukiwa; Masao Tanaka
Journal:  Clin Exp Metastasis       Date:  2002       Impact factor: 5.150

Review 6.  The clinical and functional significance of c-Met in breast cancer: a review.

Authors:  Colan M Ho-Yen; J Louise Jones; Stephanie Kermorgant
Journal:  Breast Cancer Res       Date:  2015-04-08       Impact factor: 6.466

7.  Extracellular alkaline pH leads to increased metastatic potential of estrogen receptor silenced endocrine resistant breast cancer cells.

Authors:  Maitham A Khajah; Iman Almohri; Princy M Mathew; Yunus A Luqmani
Journal:  PLoS One       Date:  2013-10-01       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.